ENTITY
BeiGene

BeiGene (6160 HK)

438
Analysis
Health Care • China
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
bullish•InnoCare Pharma Ltd
•11 Feb 2020 00:32

InnoCare Pharma IPO Initiation: Promising Prognosis

InnoCare Pharma Ltd (1576300D CH) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...

Logo
500 Views
Share
bullish•Akeso Biopharma Inc
•03 Feb 2020 13:37

Akesobio (康方生物) Pre-IPO: Late in the PD-1 Game but Products Are Promising

Akesobio is a clinical-stage biopharmaceutical company with a focus on developing biologics drugs for oncology and autoimmune. The company plans to...

Logo
709 Views
Share
bullish•S&P 500 INDEX
•20 Dec 2019 06:10

MSCI ACWI, STOXX 600 Breaking Out, Adding Fuel for Further U.S. Equity Market Rally

In today’s report we reiterate our bullish U.S. investment thesis, recap significant technical levels across indexes, and highlight attractive...

Logo
714 Views
Share
bearish•Alibaba
•25 Nov 2019 13:31

Alibaba IPO/​​​​Secondary Listing Trading - Time to Converge, That's It

Alibaba Group Holding (BABA US) raised around US$13bn (including over-allocation) via a secondary listing in Hong Kong. I've covered various...

Logo
569 Views
Share
bullish•Alibaba
•11 Nov 2019 00:25

Alibaba HK Listing: Thoughts on the Premium/Discount to the ADRs

Alibaba Group Holding (BABA US) plans to launch a $10-15 billion secondary listing in Hong Kong on 11 November, Singles Day, according to press...

Logo
1k Views
Share
x